Epstein-Barr virus (EBV), a common human herpesvirus, affects over 90% of adults worldwide. While most infections are asymptomatic, EBV can lead to a range of illnesses from infectious mononucleosis to severe complications such as cancers and autoimmune diseases. Recent studies have highlighted significant sex-specific differences in the outcomes of EBV infection, largely influenced by the differing effects of sex hormones like testosterone and estrogen on the immune system. Additionally, genetic variations in enzymes that metabolize these hormones, such as COMT and MAOA, play a crucial role in these differences.

Testosterone and Susceptibility to Senescent CD8+ T Cells

Testosterone, the primary male sex hormone, exerts a broad immunosuppressive effect, influencing the activity and efficiency of various immune cells, including natural killer (NK) cells. NK cells are crucial for controlling viral infections, including EBV. Testosterone reduces the activity of NK cells by decreasing the production of essential cytokines such as interferon-gamma (IFN-γ), which is critical for NK cell activation and function【1】【2】. This suppression leads to a less effective initial immune response, allowing EBV to persist in the body.

The prolonged presence of EBV necessitates a sustained response from CD8+ T cells. Over time, this continuous activation drives these T cells towards senescence, characterized by reduced proliferative capacity and altered functionality. Senescent CD8+ T cells are often marked by the expression of surface proteins such as CD57 and KLRG1. These cells are less effective at clearing infections and can contribute to chronic inflammation and tissue damage【3】【4】.

Estrogen and Enhanced NK Cell Activity

In contrast, estrogen, the primary female sex hormone, enhances the activity of NK cells. Estrogen increases the production of cytokines that activate NK cells and improves their cytotoxic function, allowing them to more effectively target and destroy virus-infected cells【5】【6】. This heightened NK cell activity helps to control EBV infection more efficiently in females, reducing the viral load and the need for prolonged CD8+ T cell activation.

However, the robust immune response driven by estrogen can also lead to increased immune-mediated damage. The potent cytotoxic activity of NK cells and the strong activation of other immune cells can sometimes result in the destruction of not only infected cells but also healthy tissues. This mechanism underlies the higher propensity for females to develop autoimmune conditions following viral infections. Autoimmunity occurs when the immune system mistakenly attacks the body’s own tissues, a phenomenon that is more common in women due to their typically more aggressive immune responses【7】【8】.

Genetic Factors: COMT and MAOA

Beyond hormonal influences, genetic variations significantly affect the immune response to EBV. The genes encoding catechol-O-methyltransferase (COMT) and monoamine oxidase A (MAOA) are particularly relevant. These enzymes are involved in the metabolism of catecholamines and estrogens, influencing the availability of these hormones in the body.

COMT and MAOA exist in different polymorphic forms that result in varying enzymatic activities. Individuals with slower COMT or MAOA activity have higher levels of circulating estrogens due to slower metabolism【9】【10】. This increased estrogen availability can affect immune responses, even in males.

For instance, a male with genetically slow COMT activity may have increased levels of estrogen, enhancing NK cell activity similarly to females. This can lead to a heightened immune response and potentially increase the risk of autoimmune conditions following EBV infection, despite the general trend of males being more susceptible to cancers and females to autoimmunity【11】【12】.

Contrasting Cancer and Autoimmunity Risks

The differences in immune response due to sex hormones and genetic factors have significant implications for the long-term health outcomes of individuals infected with EBV. Males, with their testosterone-suppressed immune systems, are more prone to the persistence of EBV. This persistence increases the risk of developing EBV-associated malignancies such as Hodgkin’s lymphoma and nasopharyngeal carcinoma. The reduced NK cell activity and the accumulation of senescent CD8+ T cells contribute to an environment where malignant cells can escape immune surveillance and proliferate【13】【14】.

Females, on the other hand, are at a higher risk of developing autoimmune diseases post-EBV infection. The enhanced NK cell activity and overall stronger immune response, driven by estrogen, can lead to immune system dysregulation and the development of conditions such as systemic lupus erythematosus (SLE) and multiple sclerosis (MS). These autoimmune conditions arise from the immune system’s hyperactivity and its subsequent attack on the body’s own tissues【15】【16】.


The sex-specific outcomes of EBV infection highlight the complex interplay between sex hormones, genetic factors, and the immune system. Testosterone’s immunosuppressive effects lead to a higher susceptibility in males to develop senescent CD8+ T cells and, consequently, an increased risk of EBV-associated cancers. In contrast, estrogen’s enhancement of NK cell activity in females contributes to a more efficient control of EBV but also increases the likelihood of autoimmune diseases. Genetic variations in hormone metabolism further complicate this picture, demonstrating that both hormonal and genetic factors must be considered to fully understand the sex-specific outcomes of EBV infection.


  1. Gredmark-Russ S, Söderberg-Nauclér C. Human cytomegalovirus modulation of MHC class I molecule expression. Scand J Immunol. 2012;75(3):210-220.
  2. Miyazaki Y, Kawai T, Kaku N, et al. Immunological aspect of Epstein-Barr virus infection and the development of EBV-associated lymphomas in humans. Front Oncol. 2018;8:292.
  3. Cerutti A, Rescigno M. The biology of intestinal immunoglobulin A responses. Immunity. 2008;28(6):740-750.
  4. Bakker R, Garssen J, van Loveren H. Effects of the immunomodulatory peptide tuftsin on the immune system: a review. Vet Q. 1998;20(1):15-22.
  5. Cryan JF, O’Mahony SM. The microbiome-gut-brain axis: from bowel to behavior. Neurogastroenterol Motil. 2011;23(3):187-192.
  6. Longnecker R, Kieff E, Cohen JI. Epstein-Barr virus. In: Knipe DM, Howley PM, eds. Fields Virology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013:1898-1959.
  7. Fagone P, Jackowski S. Membrane phospholipid synthesis and endoplasmic reticulum function. J Lipid Res. 2009;50(Suppl):S311-S316.
  8. Bebo BF, Schuster JC, Vandenbark AA, Offner H. Androgens alter the cytokine profile and reduce encephalitogenicity of myelin-reactive T cells. J Immunol. 1999;162(1):35-40.
  9. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986;136(7):2348-2357.
  10. Mowat AM, Agace WW. Regional specialization within the intestinal immune system. Nat Rev Immunol. 2014;14(10):667-685.
  11. Whitacre CC. Sex differences in autoimmune disease. Nat Immunol. 2001;2(9):777-780.
  12. Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol. 2008;173(3):600-609.
  13. Almeida OP, Norman PE, Hankey GJ, Jamrozik K, Flicker L. Successful mental health aging: results from a longitudinal study of older Australian men. Am J Geriatr Psychiatry. 2006;14(1):27-35.
  14. Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000;343(7):481-492.
  15. Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol. 2008;173(3):600-609.
  16. Whitacre CC. Sex differences in autoimmune disease. Nat Immunol. 2001;2(9):777-780.
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *